Zoledronic Acid For Fracture Risk Reduction Therapeutics
1. Zometa patent expiration
Treatment: Hypercalcemia of malignancy
ZOMETA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US4939130 (Pediatric) | NOVARTIS | Substituted alkanediphosphonic acids and pharmaceutical use |
Mar, 2013
(12 years ago) | |
| US4939130 | NOVARTIS | Substituted alkanediphosphonic acids and pharmaceutical use |
Sep, 2012
(13 years ago) | |
| US8324189 | NOVARTIS | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases |
May, 2025
(7 months ago) | |
| US7932241 | NOVARTIS | Pharmaceutical products comprising bisphosphonates |
Feb, 2028
(2 years from now) | |
|
US8324189 (Pediatric) | NOVARTIS | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases |
Nov, 2025
(a month ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Sep 20, 2011 |
Drugs and Companies using ZOLEDRONIC ACID ingredient
Market Authorisation Date: 20 August, 2001
Dosage: INJECTABLE
How can I launch a generic of ZOMETA before it's drug patent expiration?
More Information on Dosage
ZOMETA family patents
